Effects Of Astragalus Polysaccharide On Th17Related Cytokines In Mice Asthmatic Model

[Objective]To study the ovalbumin(OVA) sensitized asthmatic mice Thl7related cytokines ofIL-6、IL-17change, and Astragalus Polysaccharide effect and mechanism of action.[Methods]48SPF BALB/c female mice,6to8weeks of age, body weight (20±2) g, theexperimental animals were randomly divided into normal control group (Group A),asthmatic model group (group B), dexamethasone group(group C), Astragaluspolysaccharide in the low, medium and high dose group (D, E, F group), for a total ofsix groups. The model group and intervention group in l8,15days by intraperitonealinjection of0.2ml the allergens liquid (including OVA50μg). Began22days,2%OVA ato-mization6ml atomization excitation, once a day, every30minutes,atomization7days. Normal control group with saline instead of OVA-sensitized andexcited. Mice ineach group were sacrificed after the last excitation24h,bronchoalveolar lavage fluid (BALF) and the right upper lobe organizations. Rightupper leaf tissue production of paraffin sections, HE staining of lung tissuepathological changes; count the total number of BALF cell and cell sorting; usingenzyme-linked immunosorbent assay (ELISA) mice was detected in BALF IL-6,IL-17content.[Results]1. An excitation process behavior in mice observed: mice stimulate normal controlgroup (group A), no abnormal changes. Model group (group B), dexamethasonegroup (group C), APS, visible asthma-like symptoms after excitation of the high dosegroup (group D, E, F), especially in group B, C, E, lighter.2. Lung histopathological observation results: group B bronchial and peripheralvascular, pulmonary interstitial and alveolar lumen visible amount of infiltration of inflammatory cells, airway epithelial injury, structural disorder, airway endocrineamount of mucus and mucus plug formation. Group A lung airway structure clear,ciliated airway epithelial neatly arranged, no obvious change of inflammation andcollagen deposition. Group C, D, E, F has different rate to reduce, to C, E groupreduces obviously.3.BALF leukocyte count and classification: comparison of total white blood cellcount, BALF group B D, E, F than in group A, group C and group A no difference;group B, C, D, E, F of eosinophil (EOS), percentage of neutrophil (NEU)percentage, compared with the group A elevated, group C, group E, group F than ingroup B decreased.4.BALF IL-6, IL-17concentration:1)BALF IL-6content: group B than in group A, group E (P <0.05), group C, D, Fthan in group B were not statistically significant (P>0.05), group E and group Acompare difference not to have statistical significance (P>0.05).2) BALF IL-17content: group B than in group A increased significantly (P <0.01),group C, E, F than in group B decreased (P <0.05), group C, E, F and group Acompare difference not to have statistical significance (P>0.05), group E, group Fand group C comparison the difference was not statistically significant (P>0.05),group D and group B compare difference not to have statistical significance (P>0.05).(5) The correlation analysisAsthma model group BALF in of IL-6the level of IL-17. Positive correlation, ofIL-17level with the NEU and EOS showed a positive correlation.[Conclusions]1.BALB/c mice by hydrogen alumina suspension was injected intraperitoneallyOVA-atomization-excitation method is successfully established a mouse model ofasthma, the pathological changes consistent with the pathophysiology of asthma acutephase airway changes.2.In asthmatic mice, the existence of Th17-related cytokines IL-6and IL-17changes, both are elevated in asthma, and indirectly that Th17cells involved in the pathogenesis of asthma.3.APS might in part by reducing the inflammatory cells to secrete IL-6inhibition ofTh0to Th17differentiation, thereby reducing the IL-17secretion, reduce the airwayinflammation, intervention in asthma attacks; or by up-regulating macrophage IL-12expression, and promote Th0Th1differentiation, resulting in a Th1-specific cytokineIFN-gamma to inhibit Th17differentiation, reducing the IL-17secretion. Astragaluspolysaccharide secretion of IL-17inhibition of Th17better the middle dose.